Key Differentiators
- EVOH co-polymer (ethylene vinyl alcohol) with Micronized grain size of Tantalum powder
- Variety of viscosity offerings: 12 cP, 18 cP and 34 cP
- Through the STEM Trial, the SquidTM liquid embolic agent demonstrated significant reduction in treatment failure with embolization and no increase in short-term adverse events in the treatment of cSDH compared to medical treatment alone
Indication for Use
The SQUID Liquid Embolic Agent is indicated for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with symptomatic chronic subdural hematoma(s) (SDH) measuring 10 mm or greater in thickness and requiring treatment in the opinion of the neurosurgical and neurointerventional team.
Interested in learning more about this product?
Squid | Liquid Embolic
